An interventional study of Erector spinae plane block and Placebo Block in Breast Cancer, Nerve Block and Regional Anesthesia, sponsored by Women's College Hospital. Terminated at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Women's College Hospital · Not applicable, Interventional, and Treatment
The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.
Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 557th largest by enrollment of the 787 interventional ones that give a count, is one of 24 that started in 2026, is one of 204 with no phase, and was the 627th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Canada, United States
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Novartis Pharmaceuticals · Sites in Canada, United States, Australia and 1 more country
Ages 18+
British Columbia Cancer Agency · Sites in Canada
Ages 40+ · Women only
Novartis Pharmaceuticals · Sites in Canada, United States, France and 6 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
907 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 129 · Phase 2 246 · Phase 3 255 · Phase 4 25
First in 1988; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 155 across the 787 interventional studies, 199 across the 110 observational. Of the 575 that completed or were terminated, 230 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
374 of 907 have an industry lead sponsor. The 10 most frequent:
Women's College Hospital is the lead sponsor of 87 studies on the registry; 16 are open to participants now.
Women's College Hospital has 6 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Breast Neoplasms with a site in Canada that are under way reach primary completion within a year, 14 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
Add all 61 to your calendar (.ics) → With an account.
Among the 907 studies in Breast Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Regional anaesthesia combined with general anaesthesia has become common in the perioperative management of breast cancer surgery patients. Regional techniques have been recognised to provide excellent post-operative analgesia. It enhances multi-modal analgesia regimes while being opioid sparing, reducing incidence of post-operative nausea and vomiting and allowing earlier mobilisation/discharge and improving treatment success. Therefore identifying the correct regional anaesthetic technique for this group of patients is important in providing optimum peri-operative care.
The ultrasound-guided erector spinae plane (ESP) block has been recently described for the successful management of thoracic neuropathic pain. The erector spinae muscle is formed by the spinalis, longissimus thoracis, and iliocostalis muscles that run vertically in the back. The ESP block is performed by depositing the local anaesthetic in the fascial plane, deep to the erector spinae muscle, at the tip of the transverse process of the vertebra. Indirect access to the paravertebral space is gained providing analgesia without the risk of needle injury to structures in close proximity. Cadaveric studies have shown both ventral and dorsal rami of thoracic spinal nerves are affected when local anaesthetic is injected deep to the erector spinae muscle. The erector spinae muscle extends along the thoracolumbar spine allowing extensive cranio-caudal spread. The ventral ramus (intercostal nerve) is divided into the anterior and lateral branches. Its terminal branches provide the sensory innervation of the entire anterolateral wall. The dorsal ramus is divided into 2 terminal branches and it gives the sensory innervation to the posterior wall. Anterior spread of the local anaesthetic to the paravertebral space through the costotransverse foramina and the intertransverse complex provides both visceral and somatic analgesia.
While recent evidence supports statistically significant reductions in pain and opioid consumption among patients who receive an ESP block compared to systemic analgesia alone, the clinical significance of these differences are questionable the effect of ESP block on the patients' quality of recovery following ambulatory breast cancer surgery remains unclear.
Therefore, our objective is to determine whether or not the addition of an ESP block provides both superior analgesia and quality of recovery in patients undergoing ambulatory breast cancer surgery compared to systemic analgesia alone. We hypothesis that patients who received a preoperative ESP block will afford superior postoperative analgesia and improve the quality of recovery over the first 24 hours following surgery compared to those who receive a sham block for their ambulatory breast cancer surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
Procedure: Placebo Block
Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
Procedure: Erector spinae plane block
80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
Acute postoperative pain at rest
Following breast surgery, measured as an area under the curve (AUC) of rest pain scores VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable
Time frame: 24 hours postoperatively
Quality of postoperative recovery (QoR 15)
Quality of recovery at 24 hours: questionnaire (0-10, where 0 = none of the time \[poor\] and 10 = all of the time \[excellent\])
Time frame: 24 hours post-surgery
Postoperative pain scores
VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable
Time frame: 0, 6, 12, 18, 24 and 48 hours post-operatively
Intraoperative opioid consumption
Cumulative oral morphine equivalent after surgery
Time frame: During the procedure
Postoperative opioid consumption
Cumulative oral morphine equivalent after surgery
Time frame: 12,24,48 hours, 7 days postoperative
Duration of phase I (PACU) and phase II (surgical day care, SDC) stay
How fast is the recovery is-expressed in minutes
Time frame: From end of surgical procedure to 24 hours after surgery
Opioid-related side effects
Risk of opioid-related side effects(nausea, vomiting, pruritis)
Time frame: End of surgical procedure to 48 hours after surgery
Persistent post surgical pain DN4 screening tool
Satisfaction with pain management. Is prescribed pain medication enough?
Time frame: 3 months post operatively
Block-related complications
bruising at injection site, numbness over lateral chest, weakness of shoulder or arm, pain/swelling at injection site
Time frame: End of surgical procedure to 48 hours after surgery
Ran from Apr 2026 to primary completion in Apr 2026, 0 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2026 → Apr 2026, primary completion Jun 2027 → Apr 2026 and completion Jan 2028 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study.
The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women's College Hospital